Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. reported a significant 76% year-over-year increase in revenues for Q3 FY25, driven primarily by the integration of the SCN model, highlighting its ability to foster faster adoption and generate higher revenue with minimal additional investment. Service revenues experienced substantial growth, more than doubling to $4.6 million, underlining the positive impact of sleep testing and treatment centers on the company’s financial performance. With projections indicating continued revenue increases as more specialized SO teams are deployed, Vivos is well-positioned to capitalize on the growing market for sleep-disordered breathing treatments in North America and the rapidly expanding Asia Pacific region.

Vivos Therapeutics Inc. has reported a year-over-year revenue decline of 9% for the first half of 2025, primarily attributed to its transition to a new sleep center operations model, with Q2 revenues of $3.8 million falling short of estimates and showing a 6% decline from the previous year. Gross margins have decreased to 55% due to discounting and a shift in service mix, while ongoing operating losses and negative cash flow contribute to concerns regarding the company's long-term financial sustainability. Additionally, multiple risks such as increased competition, regulatory hurdles, and challenges in customer acquisition further exacerbate the negative outlook for Vivos Therapeutics's stock.